RxDoctor Payments Data

Sandeep Dube, MD

Interventional Cardiology · Indianapolis, INNPI 1952350597

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (35.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 89.0% of it on its own, with 15 other manufacturers making up the rest.

$20,881in general payments, 2019–2025

Across 129 payments — averaging $161.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$19K
  • Boston Scientific$897
  • Abbott$512
  • Cardiac Dimensions, Inc.$214
  • Biosense Webster, Inc.$128
  • Asahi Intecc USA, Inc.$106
  • plus $445 from 10 others
$182,248in research payments, 2019–2025

Across 86 payments — averaging $2119.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$179K
  • Boston Scientific$3K

What the payments were for

  • Consulting fees$7,40035%
  • Speaking & faculty fees$1,5007%
  • Travel & lodging$5,53226%
  • Food & beverage$6,43831%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,881 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$121,475
Medicare patients
219
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium28$137
Rosuvastatin Calcium13$49

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →